氟哌啶醇
參考文獻

↑  . Drugs.com. 2020-02-10  [2020-09-13].
1 2 3 4 5 6 7 8  Kudo S, Ishizaki T. . Clinical Pharmacokinetics. December 1999, 37 (6): 435–456. PMID 10628896. S2CID 71360020. doi:10.2165/00003088-199937060-00001.
↑  Kostrzewa RM. . . Cham: Springer International Publishing. 2022: 159–198. ISBN 978-3-031-15079-1. doi:10.1007/978-3-031-15080-7_53.
↑  Igarashi, Kazuo. . Journal of Toxicology: Toxin Reviews. 1998, 17 (1): 27–38. ISSN 0731-3837. doi:10.3109/15569549809006488.
↑  Górska A, Marszałł M, Sloderbach A.  [The neurotoxicity of pyridinium metabolites of haloperidol]. Postepy Hig Med Dosw (Online). October 2015, 69: 1169–1175. PMID 26561842. doi:10.5604/17322693.1175009  (不活跃 2024-11-01) （Polish）.  引文格式1维护：未识别语文类型 (link)
↑   (PDF). TGA eBusiness Services. Aspen Pharma Pty Ltd. 2011-09-29  [2014-05-29]. （原始内容存档于2017-03-14）.
1 2 3 4 5 6 7 8 9 10  . The American Society of Health-System Pharmacists.   [2015-01-02]. （原始内容存档于2015-01-02）.
1 2  Schuckit MA. . The New England Journal of Medicine. November 2014, 371 (22): 2109–2113. PMID 25427113. S2CID 205116954. doi:10.1056/NEJMra1407298.
↑  Plosker GL. . PharmacoEconomics. July 2012, 30 (7): 611–631. PMID 22559293. doi:10.2165/11208500-000000000-00000.
↑  . Australian Government. 2014-03-03  [2015-01-02]. （原始内容存档于2014-04-08）.
↑  Sneader W.  Rev. and updated. Chichester: Wiley. 2005: 124. ISBN 978-0-471-89979-2. （原始内容存档于2015-12-08）.
↑  Ravina E.  1. Aufl. Weinheim: Wiley-VCH. 2011: 62. ISBN 978-3-527-32669-3. （原始内容存档于2015-12-08）.
↑  World Health Organization. . Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
↑  Stevens A.  2nd. Abingdon: Radcliffe Medical. 2004: 202. ISBN 978-1-85775-892-4. （原始内容存档于2015-12-08）.
↑  . ClinCalc.   [2022-10-07].
↑  Giannini AJ, Underwood NA, Condon M. . American Journal of Therapeutics. November 2000, 7 (6): 389–391. PMID 11304647. doi:10.1097/00045391-200007060-00008.
↑  Giannini AJ, Eighan MS, Loiselle RH, Giannini MC. . Journal of Clinical Pharmacology. April 1984, 24 (4): 202–204. PMID 6725621. S2CID 42278510. doi:10.1002/j.1552-4604.1984.tb01831.x.
1 2 3  . Drugs.com.   [2013-10-03]. （原始内容存档于2013-10-05）.
↑  Joint Formulary Committee.  65th. London, England: Pharmaceutical Press. 2013: 229–30. ISBN 978-0-85711-084-8.
1 2  Brayfield, A (编). . Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. 2013 -12-13  [2014-05-29].  请检查|date=中的日期值 (帮助)
1 2  Currier GW. . Journal of Psychiatric Practice (Lippincott Williams & Wilkins). January 2003, 9 (1): 59–70. PMID 15985915. S2CID 22342074. doi:10.1097/00131746-200301000-00006.
↑  Cavanaugh SV. . The Medical Clinics of North America. September 1986, 70 (5): 1185–1202. PMID 3736271. doi:10.1016/S0025-7125(16)30919-1.
↑  Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. . Postgraduate Medicine. May 2001, (Spec No): 1–88; quiz 89–90. PMID 11500996.
↑  Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. . Journal of Psychiatric Practice. January 2003, 9 (1): 16–38. PMID 15985913. S2CID 29363701. doi:10.1097/00131746-200301000-00004.
↑  Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. . Journal of Psychiatric Practice. November 2005, 11 (Suppl 1): 5–25. PMID 16319571. S2CID 72366588. doi:10.1097/00131746-200511001-00002.
1 2  Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. . Lancet. September 2013, 382 (9896): 951–962. PMID 23810019. S2CID 32085212. doi:10.1016/S0140-6736(13)60733-3.
↑  Halman A, Kong G, Sarris J, Perkins D. . J Psychopharmacol. January 2024, 38 (1): 3–18. PMC 10851641 . PMID 37982394. doi:10.1177/02698811231211219.
↑  Halberstadt AL. . Behav Brain Res. January 2015, 277: 99–120. PMC 4642895 . PMID 25036425. doi:10.1016/j.bbr.2014.07.016.
↑  Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. . NeuroReport. December 1998, 9 (17): 3897–3902. PMID 9875725. doi:10.1097/00001756-199812010-00024.
↑  . 2018-10-31  [2019-01-18].
↑  . CHEMEUROPE.com.   [2024--12-14].  请检查|access-date=中的日期值 (帮助)
↑  Work Group on Schizophrenia.  Second.   [2014-04-21]. （原始内容存档于2012-03-27）.
↑ American Academy of Hospice and Palliative Medicine. . Choosing Wisely: An Initiative of the ABIM Foundation (American Academy of Hospice and Palliative Medicine). [ 2013-08-01 ] . （原始内容存档于2013-09-01）. , which cites
Smith TJ, Ritter JK, Poklis JL, Fletcher D, Coyne PJ, Dodson P, Parker G. . Journal of Pain and Symptom Management. May 2012, 43 (5): 961–966. PMID 22560361. doi:10.1016/j.jpainsymman.2011.05.017 .
Weschules DJ. . Journal of Palliative Medicine. December 2005, 8 (6): 1135–1143. PMID 16351526. doi:10.1089/jpm.2005.8.1135.
↑  FDA Psychopharmacological Drugs Advisory Committee.  (PDF). Food and Drug Administration. 2000-07-09  [2016-09-30]. （原始内容 (PDF)存档于2017-01-19）.
↑  Nasrallah HA, Chen AT. . Annals of Clinical Psychiatry. August 2017, 29 (3): 195–202. PMID 28738100.
↑  .
↑  Sattler, Stefan M; Lubberding, Anniek F. . IJC Heart & Vasculature. 2019-12-30, 26 (100455)  [2024-12-15]. doi:10.1016/j.ijcha.2019.100455.
↑  Nasrallah HA, Chen AT. . Annals of Clinical Psychiatry. August 2017, 29 (3): 195–202. PMID 28738100.
↑  Pierre JM. . Current Psychiatry: 19.
↑  Joint Formulary Committee, BMJ (编). .  57. United Kingdom: Royal Pharmaceutical Society of Great Britain. March 2009: 192. ISBN 978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
1 2  Haddad PM, Dursun S, Deakin B. . OUP Oxford. 2004: 207–216. ISBN 9780198527480 （英语）.
↑  . （原始内容存档于2011-11-22）.
↑  Seeman P, Tallerico T. . Molecular Psychiatry. March 1998, 3 (2): 123–134. PMID 9577836. doi:10.1038/sj.mp.4000336 .
↑  . www.medicines.org.uk.   [2021-12-26].
↑  . （原始内容存档于2011-08-10）.
↑  Shan X, Williams AC, Khutoryanskiy VV.  (PDF). International Journal of Pharmaceutics. November 2020, 590: 119884. PMID 32950665. S2CID 221826541. doi:10.1016/j.ijpharm.2020.119884.
↑   (PDF).
↑  Healy D.  1. London: Chapman and Hall. 1996. ISBN 978-1-86036-008-4. [页码请求]
1 2  Granger B, Albu S. . Annals of Clinical Psychiatry. 2005, 17 (3): 137–140. PMID 16433054. doi:10.1080/10401230591002048.
↑  López-Muñoz F, Alamo C. . Brain Research Bulletin. April 2009, 79 (2): 130–141. PMID 19186209. S2CID 7720401. doi:10.1016/j.brainresbull.2009.01.005.
↑  Escobar JI, Marin H. . World Scientific. 2013: 69. ISBN 978-981-4578-37-0 （英语）.
↑  Adams JG. . Elsevier Health Sciences. 2012: 1635. ISBN 978-1-4557-3394-1 （英语）.
↑  . Hölzel.   [2024-12-14].
1 2  . AdisInsight. 27 August 2019  [13 August 2024].
1 2  Kennedy SH, Giacobbe P, Placenza F, Hudson CJ, Seeman P, Seeman MV. . J Affect Disord. September 2014, 166: 139–143. PMID 25012422. doi:10.1016/j.jad.2014.04.014.
↑  Cohen D, Recalt A. . Psychother Psychosom. 2019, 88 (2): 96–104. PMID 30923288. doi:10.1159/000496733.
↑  Hofmeyr JM. . Journal of the South African Veterinary Association. December 1981, 52 (4): 273–282. PMID 6122740.
Template:Navboxes
Template:Portal bar
氟哌啶醇癸酸酯（英语：）的鍵線式結構。癸酸酯基團以紅色標示。
氟哌啶醇10毫克口服片劑。
氟哌啶醇奎酸酯（英语：）肌肉注射劑。